Management of non-cystic fibrosis bronchiectasis

Stacey K. Dull, Brooke D. Havlat, Michael J. Sanley, Mark A. Malesker

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The purpose of this report is to describe the case of a 43-year-old male with asthma who was hospitalized for an exacerbation of non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease that is characterized by dilation of the airways, persistent cough, chronic sputum production, and recurrent respiratory infections. He was treated with oral and inhaled antibiotics, inhaled bronchodilators, and aggressive airway-clearance techniques including nebulized 7% sodium chloride, flutter valve, and high-frequency chest wall oscillation. SETTINGS: Community pharmacy, nursing facility pharmacy, consultant pharmacy practice. PRACTICE CONSIDERATIONS: As the number of patients diagnosed with NCFB continues to increase, it is crucial to recognize that specific guidance for management of NCFB is warranted, as treatment responses differ from cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease. CONCLUSION: It is important for pharmacists to understand the pharmacologic and nonpharmacologic treatments for NCFB to better assist physicians and patients and improve therapeutic outcomes.

Original languageEnglish (US)
Pages (from-to)658-666
Number of pages9
JournalConsultant Pharmacist
Volume33
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Bronchiectasis
Fibrosis
Chest Wall Oscillation
Pharmacies
Bronchodilator Agents
Consultants
Sputum
Pharmacists
Cough
Cystic Fibrosis
Sodium Chloride
Respiratory Tract Infections
Chronic Obstructive Pulmonary Disease
Lung Diseases
Dilatation
Nursing
Chronic Disease
Therapeutics
Asthma
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Management of non-cystic fibrosis bronchiectasis. / Dull, Stacey K.; Havlat, Brooke D.; Sanley, Michael J.; Malesker, Mark A.

In: Consultant Pharmacist, Vol. 33, No. 11, 01.11.2018, p. 658-666.

Research output: Contribution to journalArticle

Dull, Stacey K. ; Havlat, Brooke D. ; Sanley, Michael J. ; Malesker, Mark A. / Management of non-cystic fibrosis bronchiectasis. In: Consultant Pharmacist. 2018 ; Vol. 33, No. 11. pp. 658-666.
@article{939d7fb01dd24829bb089a9fafed3a55,
title = "Management of non-cystic fibrosis bronchiectasis",
abstract = "OBJECTIVE: The purpose of this report is to describe the case of a 43-year-old male with asthma who was hospitalized for an exacerbation of non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease that is characterized by dilation of the airways, persistent cough, chronic sputum production, and recurrent respiratory infections. He was treated with oral and inhaled antibiotics, inhaled bronchodilators, and aggressive airway-clearance techniques including nebulized 7{\%} sodium chloride, flutter valve, and high-frequency chest wall oscillation. SETTINGS: Community pharmacy, nursing facility pharmacy, consultant pharmacy practice. PRACTICE CONSIDERATIONS: As the number of patients diagnosed with NCFB continues to increase, it is crucial to recognize that specific guidance for management of NCFB is warranted, as treatment responses differ from cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease. CONCLUSION: It is important for pharmacists to understand the pharmacologic and nonpharmacologic treatments for NCFB to better assist physicians and patients and improve therapeutic outcomes.",
author = "Dull, {Stacey K.} and Havlat, {Brooke D.} and Sanley, {Michael J.} and Malesker, {Mark A.}",
year = "2018",
month = "11",
day = "1",
doi = "10.4140/TCP.n.2018.658",
language = "English (US)",
volume = "33",
pages = "658--666",
journal = "The Senior care pharmacist",
issn = "2639-9636",
publisher = "American Society of Consultant Pharmacists",
number = "11",

}

TY - JOUR

T1 - Management of non-cystic fibrosis bronchiectasis

AU - Dull, Stacey K.

AU - Havlat, Brooke D.

AU - Sanley, Michael J.

AU - Malesker, Mark A.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - OBJECTIVE: The purpose of this report is to describe the case of a 43-year-old male with asthma who was hospitalized for an exacerbation of non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease that is characterized by dilation of the airways, persistent cough, chronic sputum production, and recurrent respiratory infections. He was treated with oral and inhaled antibiotics, inhaled bronchodilators, and aggressive airway-clearance techniques including nebulized 7% sodium chloride, flutter valve, and high-frequency chest wall oscillation. SETTINGS: Community pharmacy, nursing facility pharmacy, consultant pharmacy practice. PRACTICE CONSIDERATIONS: As the number of patients diagnosed with NCFB continues to increase, it is crucial to recognize that specific guidance for management of NCFB is warranted, as treatment responses differ from cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease. CONCLUSION: It is important for pharmacists to understand the pharmacologic and nonpharmacologic treatments for NCFB to better assist physicians and patients and improve therapeutic outcomes.

AB - OBJECTIVE: The purpose of this report is to describe the case of a 43-year-old male with asthma who was hospitalized for an exacerbation of non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease that is characterized by dilation of the airways, persistent cough, chronic sputum production, and recurrent respiratory infections. He was treated with oral and inhaled antibiotics, inhaled bronchodilators, and aggressive airway-clearance techniques including nebulized 7% sodium chloride, flutter valve, and high-frequency chest wall oscillation. SETTINGS: Community pharmacy, nursing facility pharmacy, consultant pharmacy practice. PRACTICE CONSIDERATIONS: As the number of patients diagnosed with NCFB continues to increase, it is crucial to recognize that specific guidance for management of NCFB is warranted, as treatment responses differ from cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease. CONCLUSION: It is important for pharmacists to understand the pharmacologic and nonpharmacologic treatments for NCFB to better assist physicians and patients and improve therapeutic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85056803261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056803261&partnerID=8YFLogxK

U2 - 10.4140/TCP.n.2018.658

DO - 10.4140/TCP.n.2018.658

M3 - Article

C2 - 30458908

AN - SCOPUS:85056803261

VL - 33

SP - 658

EP - 666

JO - The Senior care pharmacist

JF - The Senior care pharmacist

SN - 2639-9636

IS - 11

ER -